Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Randomized, Masked, Placebo-Controlled Trial of an AI-Guided Microbiome-Targeted Nutritional Intervention for Glycemic Improvement in Adults With Type 2 Diabetes: The AIM-MET Trial

NCT07622628 is registered in ClinicalTrials.gov with ENBIOSIS BIOTECHNOLOGIES as lead sponsor.

NCT NCT07622628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07622628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Randomized, Masked, Placebo-Controlled Trial of an AI-Guided Microbiome-Targeted Nutritional Intervention for Glycemic Improvement in Adults With Type 2 Diabetes: The AIM-MET Trial
Lead sponsor
ENBIOSIS BIOTECHNOLOGIES
Phase
Not applicable
Overall status
Recruiting
Start date
June 1, 2026
Completion date
June 30, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2, type 2 diabetes